RESUMO
This study investigated the effect of calcium (Ca) and phytase interaction on growth performance and bone quality in 1-42-day-old broiler chickens. A total of 624 female one-day-old Ross 308 broilers were allotted to 13 treatments with four replicates and 12 birds per replicate. A 2 × 6 factorial experiment was designed to test the combinations of 0.50% and 1.00% Ca with 0, 500, 1,000, 2,500, 5,000, and 10,000 FTU/kg phytase in the basal diet (0.25% non-phytate phosphorus, NPP). The control diet contained adequate Ca and phosphorus (P). Dietary Ca, phytase, and their interaction affected growth performance and bone mineralization of broilers at 1-42 days of age (p<0.05). The broilers fed with 1.00% Ca had lower body weight gain (BWG) and feed intake (FI) compared with the birds fed with 0.50% Ca (p<0.05). The BWG, FI, leg bone weight, and ash weight of the broilers fed with 0.25% NPP were lower than those of birds fed with the control diet (p<0.05). The addition of 500-10,000 FTU/kg phytase improved growth rate and leg bone quality, especially at 1.00% Ca (p<0.05). No differences were observed in growth performance and bone quality of 42-day-old broilers fed with 1.00% Ca + 2,500-10,000 FTU/kg phytase and the control diet (p>0.05). These data indicated that high doses of phytase (2,500-10,000 FTU/kg) alleviate the negative effects of Ca and P imbalance (Ca-to-NPP ratio = 4.0) on growth performance and bone mineralization of broiler chickens.(AU)
Assuntos
Animais , Feminino , Calcificação Fisiológica/efeitos dos fármacos , Galinhas/fisiologia , Fósforo/análise , Cálcio da Dieta/análise , Fenômenos Fisiológicos da Nutrição AnimalRESUMO
The objective of this study was to investigate the optimal zinc (Zn) requirement of broiler chickens based on Zn retention. On the day of hatch, 350 male Ross 308 broilers were randomly assigned to seven treatments with five replicates of ten birds each. Zinc was supplemented as ZnSO4·7H2O at 0, 20, 40, 60, 80, 100, or 120 mg/kg in the starter diet (fed from 1 to 21 d of age) and at 0, 16, 32, 48, 64, 80, or 96 mg/kg in the grower diet (fed from 22 to 42 d of age). The analyzed Zn levels were 34.98 and 27.57 mg/kg in the basal starter and grower diets, respectively. Supplemental Zn levels did not influence body weight gain, feed intake, feed conversion ratio, or liver Zn content of broilers at 21 and 42 d of age (p>0.05). Tibia ash Zn content of 21-d-old broilers increased when Zn supplementation level increased from 0 to 40 mg/kg Zn in (p<0.05). The highest breast muscle Zn content in 42-d-old broilers was observed when 100 and 80 mg Zn/kg was supplemented in the starter and grower diets, respectively. Fecal Zn content, Zn intake, Zn excretion, and Zn retention of 31- to 33-d-old broilers linearly increased with supplemental Zn levels (p<0.05). Zinc retention values, calculated as the difference between Zn intake and Zn excretion, were negative, about zero, and positive when starter/grower diets were supplemented with 0/0 and 20/16, 40/32, and 60/48 and 120/96 mg/kg, respectively. These results indicate that supplementing 40 and 32 mg Zn/kg in starter and grower diets, respectively, promote the growth performance of broiler chickens, while reduce Zn excretion in the environment.
Assuntos
Animais , Aves Domésticas/fisiologia , Aves Domésticas/metabolismo , Zinco/análise , Zinco/efeitos adversosRESUMO
The objective of this study was to investigate the optimal zinc (Zn) requirement of broiler chickens based on Zn retention. On the day of hatch, 350 male Ross 308 broilers were randomly assigned to seven treatments with five replicates of ten birds each. Zinc was supplemented as ZnSO4·7H2O at 0, 20, 40, 60, 80, 100, or 120 mg/kg in the starter diet (fed from 1 to 21 d of age) and at 0, 16, 32, 48, 64, 80, or 96 mg/kg in the grower diet (fed from 22 to 42 d of age). The analyzed Zn levels were 34.98 and 27.57 mg/kg in the basal starter and grower diets, respectively. Supplemental Zn levels did not influence body weight gain, feed intake, feed conversion ratio, or liver Zn content of broilers at 21 and 42 d of age (p>0.05). Tibia ash Zn content of 21-d-old broilers increased when Zn supplementation level increased from 0 to 40 mg/kg Zn in (p<0.05). The highest breast muscle Zn content in 42-d-old broilers was observed when 100 and 80 mg Zn/kg was supplemented in the starter and grower diets, respectively. Fecal Zn content, Zn intake, Zn excretion, and Zn retention of 31- to 33-d-old broilers linearly increased with supplemental Zn levels (p<0.05). Zinc retention values, calculated as the difference between Zn intake and Zn excretion, were negative, about zero, and positive when starter/grower diets were supplemented with 0/0 and 20/16, 40/32, and 60/48 and 120/96 mg/kg, respectively. These results indicate that supplementing 40 and 32 mg Zn/kg in starter and grower diets, respectively, promote the growth performance of broiler chickens, while reduce Zn excretion in the environment.(AU)
Assuntos
Animais , Zinco/efeitos adversos , Zinco/análise , Aves Domésticas/metabolismo , Aves Domésticas/fisiologiaRESUMO
It has been suggested that selected COX inhibitors can overcome multidrug resistance through the inhibition of ATPbinding cassette-transporter proteins thereby enhancing the inhibitory effect of doxorubicin on human tumor growth and promoting the actions of cytostatics. However, their effect on lung cancer and the molecular mechanisms involved in the overcoming of multidrug resistance are unclear. In the present study, the ability of meloxicam, a COX-2-specific inhibitor to enhance doxorubicinmediated inhibition was investigated in human A549 lung cancer in vivo and in vitro. In order to unravel the molecular mechanisms involved in doxorubicin accumulation, we measured the levels of multidrug resistance-associated protein (MRP)-transporter protein activity and expression by western blotting, since this has been implicated in meloxicam action as well as in chemoresistance. We found that, in A549 cells, meloxicam could increase intracellular accumulation of doxorubicin, a substrate for MRP, through inhibition of cellular export. Western blot analysis indicated that meloxicam reduced the expression of MRP1 and MRP4. The results reported in the present study demonstrate for the first time that the specific COX-2 inhibitor meloxicam can increase the intracellular accumulation of doxorubicin and enhance doxorubicin-induced cytotoxicity in A549 cancer cells by reducing the expression of MRP1 and MRP4.
Assuntos
Ciclo-Oxigenase 2/genética , Neoplasias Pulmonares/tratamento farmacológico , Proteínas Associadas à Resistência a Múltiplos Medicamentos/biossíntese , Tiazinas/administração & dosagem , Tiazóis/administração & dosagem , Linhagem Celular Tumoral , Inibidores de Ciclo-Oxigenase 2/administração & dosagem , Doxorrubicina/administração & dosagem , Resistência a Múltiplos Medicamentos/genética , Resistencia a Medicamentos Antineoplásicos/genética , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Meloxicam , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genéticaRESUMO
Many studies have shown that the pathogenesis of liver injury includes oxidative stress. MicroRNA-122 may be a marker for the early diagnosis of drug-induced liver injury. However, the relationship between microRNA-122 and oxidative stress in anti-tuberculosis drug-induced liver injury remains unknown. We measured changes in tissue microRNA-122 levels and indices of oxidative stress during liver injury in mice after administration of isoniazid, a first-line anti-tuberculosis drug. We quantified microRNA-122 expression and indices of oxidative stress at 7 time points, including 1, 3, and 5 days and 1, 2, 3, and 4 weeks. The tissue microRNA-122 levels and oxidative stress significantly changed at 3 and 5 days, suggesting that isoniazid-induced liver injury reduces oxidative stress and microRNA-122 expression compared to in the control group (P < 0.05). Notably, over the time course of isoniazid-induced liver injury, mitochondrial ribosome protein S11 gene, the target of microRNA-122, began to change at 5 days (P < 0.05). The tissue microRNA-122 profile may affect oxidative stress by regulating mitochondrial ribosome protein S11 gene during isoniazid-induced liver injury, which may contribute to the response mechanisms of microRNA-122 and oxidative stress.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/genética , MicroRNAs/genética , Estresse Oxidativo/genética , Animais , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/patologia , Modelos Animais de Doenças , Feminino , Expressão Gênica , Isoniazida/efeitos adversos , Testes de Função Hepática , Masculino , Metalotioneína/metabolismo , Camundongos , Oxirredução , Fatores de TempoRESUMO
Morphine is a psychoactive medication that is used as a standard analgesic treatment to relieve pain in clinics. Many patients rely on chronic or acute treatment of morphine to treat pain. However, morphine is a narcotic and has a reverse effect when inappropriately used. Therefore, it is necessary to study chronic and acute morphine treatment to improve pain relief. In this study, differentially expressed genes of acute and chronic morphine-treated mice were identified using Array Express datasets. The genes that were associated with these two types of morphine treatment are discussed. A co-expression network was constructed, and the hub genes were identified. Gene ontology enrichment analysis and pathway analysis were performed using the Gene Ontology website and Kyoto Encyclopedia of Genes and Genomes, respectively. Our study revealed genes that are associated with acute and chronic morphine treatment. Therefore, this study is potentially useful for improving pain relief of patients by acute and chronic morphine treatment.
Assuntos
Bases de Dados Genéticas , Perfilação da Expressão Gênica , Regulação da Expressão Gênica/efeitos dos fármacos , Morfina/farmacologia , Análise de Sequência com Séries de Oligonucleotídeos/métodos , Animais , Ontologia Genética , Redes Reguladoras de Genes/efeitos dos fármacos , CamundongosRESUMO
The aim of this study was to observe the analgesic effects of the combination of dezocine and butorphanol on postoperative cognitive function in elderly patients. Forty elderly patients undergoing upper abdominal surgeries or thoracotomies with general anesthesia were randomly divided into the dezocine and butorphanol group or the butorphanol group (20 patients per group). A visual analog scale was used to evaluate analgesia and the degree of malignant vomiting. The Ramsay scoring method was used to evaluate sedation. The Mini-Mental State Examination (MMSE) was used to evaluate cognitive function. Forty-eight hours after the operation, the pain score of the dezocine and butorphanol group (means ± SD, 1.75 ± 0.44) was lower than that of the butorphanol group (2.25 ± 0.79; P < 0.05), and the nausea and vomiting score of the dezocine and butorphanol group (0) was lower than that of the butorphanol group (0.70 ± 1.30; P < 0.05). Six hours after the operation, the sedative score of the butorphanol group (3.75 ± 0.79) was higher than that of the dezocine and butorphanol group (2.15 ± 0.75; P < 0.05). Compared to 1 day before the operation, the MMSE scores of both groups decreased 6 h after the operation, and the MMSE score of the butorphanol group (15.00 ± 2.00) was lower than that of the dezocine and butorphanol group (20.95 ± 1.54; P < 0.05). Dezocine and butorphanol analgesia had transient effects on postoperative cognitive function in elderly patients, and the effect of the combination was superior than butorphanol only.
Assuntos
Anestesia Intravenosa/efeitos adversos , Compostos Bicíclicos Heterocíclicos com Pontes/efeitos adversos , Butorfanol/efeitos adversos , Cognição/efeitos dos fármacos , Tetra-Hidronaftalenos/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Compostos Bicíclicos Heterocíclicos com Pontes/administração & dosagem , Butorfanol/administração & dosagem , Feminino , Humanos , Hipnóticos e Sedativos/administração & dosagem , Masculino , Dor/tratamento farmacológico , Dor/patologia , Complicações Pós-Operatórias , Tetra-Hidronaftalenos/administração & dosagem , ToracotomiaRESUMO
The objective of this study was to determine the changes in peripheral blood circulating tumor cells in HER2-positive early breast cancer before and after Herceptin therapy, and to explore the effects of the HER2 gene and Herceptin on circulating tumor cells. CK19 mRNA expression in peripheral blood was evaluated by qRT-PCR as an index of circulating tumor cells in 15 cases of HER-2-positive breast cancer and 18 cases of HER2-negative breast cancer before, and after chemotherapy as well. Ten cases of HER2-positive breast cancer continued on Herceptin therapy for 3 months after chemotherapy, and their peripheral blood was again drawn and assayed for CK-19 mRNA expression. Preoperatively, all cases of HER2-positive cancer were positive for CK19 mRNA in peripheral blood, but 6 cases of HER2-negative breast cancer were positive (33.3%), where there was a substantial difference between the two groups. After 6 cycles of adjuvant chemotherapy, CK19 positive rates in cases of HER2-positive and -negative breast cancer reduced by 93.3 and 11.1%, respectively, with a significant difference still existing. After 3 months of Herceptin therapy, expression of CK19 mRNA declined considerably in 10 cases of HER2 positive breast cancer (113.66 ± 88.65 vs 63.35 ± 49.27, P = 0.025). HER-2 gene expression closely correlated with circulating tumor cells in peripheral blood of early breast cancer patients. Moreover, Herceptin, a monoclonal antibody for HER2, can reduce the number of circulating tumor cells, which can be an early predictive factor for Herceptin therapy effectiveness against breast cancer.
Assuntos
Antineoplásicos/farmacologia , Neoplasias da Mama/tratamento farmacológico , Células Neoplásicas Circulantes/efeitos dos fármacos , Trastuzumab/farmacologia , Antineoplásicos/administração & dosagem , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Neoplasias da Mama/sangue , Neoplasias da Mama/enzimologia , Neoplasias da Mama/cirurgia , Feminino , Estudos de Associação Genética , Humanos , Queratina-19/biossíntese , Queratina-19/sangue , Queratina-19/genética , Prognóstico , Receptor ErbB-2/biossíntese , Receptor ErbB-2/genética , Trastuzumab/administração & dosagemRESUMO
This study evaluated the effects of dietary non-phytate phosphorus (NPP) and 1a-hydroxycholecalciferol (1a-OH-D3) on the growth performance, bone mineralization, and carcass traits of 1- to 21-day-old broiler chickens. On the day of hatch, 600 male Ross 308 chicks were weighed and randomly assigned to 12 treatments, with five cages of 10 birds each. A 6 × 2 factorial arrangement was applied, consisting of 0.20%, 0.25%, 0.30%, 0.35%, 0.40%, or 0.45% NPP and 0 or 5 g/kg of 1a-OH-D3. The basal diet contained 0.52% calcium (Ca) and was not supplemented with vitamin D3. Dietary NPP levels significantly affected growth performance and tibia mineralization (except width) of broilers; by contrast, meat yield and organ relative weight were not influenced by NPP. The inclusion of 1a-OH-D3 improved growth performance, tibia mineralization, and carcass and breast yield, whereas it decreased the relative weights of the liver, heart, and kidney. A significant interaction between NPP and 1a-OH-D3 was observed for body weight gain (BWG), feed efficiency (FE), mortality, serum Ca and P levels, tibia breaking-strength, ash weight, and Ca content, as well as breast yield and heart relative weight. These results suggest that broilers fed with 5 g of 1a-OH-D3 per kg of diet obtain optimal growth performance and tibia mineralization when dietary NPP level was 0.30% and the analyzed Ca to NPP ratio was 1.97.(AU)
Assuntos
Animais , Aves Domésticas/crescimento & desenvolvimento , Carne/efeitos adversos , Carne/análise , Vitamina D/análogos & derivados , Vitamina D/efeitos adversos , Vitamina D/análiseRESUMO
This study aimed at comparing the growth and mineralization of the femur, tibia, and metatarsus of male and female broiler chicks. On the day of hatch, 100 male and 100 female Ross 308 broiler chicks were transferred stainless cages with 10 birds per cage. On d 7, 14, 21, 28, 35, and 42, five males and five females were sacrificed and their femur, tibia, and metatarsus were collected. Results showed that the tibia was the heaviest and the longest and contained the highest content of ash and calcium (Ca) among the three leg bones. The femur had the greatest diameter. The weight, length, diameter, and ash weight of the femur, tibia, and metatarsus linearly increased with age. The ash, Ca, and phosphorus (P) content in the femur and the tibia quadratically increased with age; by contrast, these parameters in the metatarsus linearly increased with age. The bones grew faster in 1 to 21 d of age. The weight, diameter, and ash weight of the three bones of males were higher than those of females. The Ca to P ratio of the three bones (femur, tibia, and metatarsus) was approximately 2.0:1. These data indicate that there are differences in bone growth and mineralization among the femur, tibia, and metatarsus of male or female broiler chicks.